HOME >> MEDICINE >> NEWS
First medication to target PCP addiction is reported by Arkansas researchers

Animal studies by researchers at the University of Arkansas for Medical Sciences (UAMS) used an antibody-based drug to provide immediate protection against the chronic abuse of phencyclidine (PCP). The studies mark the first time that a long-acting treatment has been developed to block or reduce the psychoactive effects of PCP in drug addicts, according to UAMS scientist S. Michael Owens, Ph.D. In earlier studies, he used a smaller fragment of the antibody to treat drug overdose.

Owens presented his findings here today at the national meeting of the American Chemical Society, the world's largest scientific society.

Owens said his new technique uses monoclonal antibodies-identical copies of animal antibodies cloned and reproduced in the laboratory-to prevent or slow the entry of PCP into the brain, where it produces its pleasurable effects. The ability to create huge quantities of these antibodies makes it possible to administer a very large dose in a single injection. In the animal studies, just one injection curbed the effects of PCP for at least two weeks-a period equivalent to one to two months in humans, Owens said.

This fast-acting therapy could make a profound difference in the way PCP addicts are treated, enabling doctors to offer addicts an effective anti-addiction medication that works immediately. By contrast, antibody-based approaches to creating vaccines entail weeks of waiting before benefits appear, Owens said.

PCP triggers hallucinations, psychotic behavior, violence, and even self-destruction.

In a 1997 NIDA survey of high school seniors, more than two percent of the students said they had used PCP in the preceding 30 days. "Young people are attracted to PCP even though they know how dangerous it is, because it is inexpensive and because it produces euphoria, hallucinations and a feeling of superhuman strength," said Owens.

The UAMS research is supported by grants from the National Institute for Drug Ab
'"/>

Contact: Charmayne Marsh
y_marsh@acs.org
202-872-4445
American Chemical Society
24-Aug-1999


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... 2016 , ... A quote from Dr. Edward Hallowell, host of CRN International’s ... offer a rare glimpse into the mind of those people with ADHD. , Dr. ... author, has described people with ADHD as having “Ferrari engines for a brain, with ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... consultation services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann ... basketball coach who needs treatment for a brain tumor. , Jason Bauer and ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm ... Boroughs, is launching a charity drive to raise funds that will benefit the Marine ... of marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser ... Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through ... Phoenix Valley with Delightful Deals on Botox® and Juvederm® just in time ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 2016 BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s ... achieved through user experience. , BOC Global Events & Training Group is a ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... NEW YORK , Dec. 7, 2016 /PRNewswire/ ... urinary incontinence, urinary retention and other urological disorders. ... catheter and external (condom) catheter. Indwelling or Foley ... both ends. This type of catheter is inserted ... in the bladder. A tiny balloon attachment at ...
(Date:12/7/2016)... , Dec. 7, 2016 A new investigational drug ... human clinical trials in search of the world,s first treatment ... publication of research findings today in the journal ... will be a watershed moment for millions of people living ... director of Van Andel Research Institute,s Center ...
(Date:12/7/2016)... , Dec. 7, 2016  Northwest Biotherapeutics ... the "Company"), a biotechnology company developing DCVax® personalized ... that the Nasdaq Staff has not accepted the ... Listing Rules previously reported, and the Company has ... the Company,s common stock from listing on Nasdaq. ...
Breaking Medicine Technology:
Cached News: